Terug
48
27
Ook genoteerd als
FLMNY
OTC
Dagbereik
€ 52,85
€ 52,90
52-Weeksbereik
€ 42,54
€ 64,00
Volume
200
50D / 200D Gem.
€ 57,63
/
€ 60,50
Vorige Slotkoers
€ 52,85
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (627 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 29,2 | 0,3 |
| P/B | 4,9 | 2,9 |
| ROE % | 18,0 | 3,7 |
| Net Margin % | 6,7 | 3,8 |
| Rev Growth 5Y % | 12,2 | 10,0 |
| D/E | 1,0 | 0,2 |
Koersdoel Analisten
Geen analistendekking beschikbaar
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2029 |
€ 3,50
€ 3,41 – € 3,57
|
2,9 B | 6 |
| FY2028 |
€ 3,34
€ 3,26 – € 3,41
|
2,9 B | 7 |
| FY2027 |
€ 3,00
€ 2,93 – € 3,07
|
2,7 B | 6 |
Belangrijkste Punten
Revenue grew 12,19% annually over 5 years — strong growth
Earnings grew 21,90% over the past year
ROE of 17,99% — decent returns on equity
Generating 327,41M in free cash flow
Cash machine — converts 215,25% of earnings into free cash flow
Capital efficient — spends only 3,65% of revenue on capex
Groei
Revenue Growth (5Y)
12,19%
Revenue (1Y)14,98%
Earnings (1Y)21,90%
FCF Growth (3Y)33,87%
Kwaliteit
Return on Equity
17,99%
ROIC14,45%
Net Margin6,72%
Op. Margin15,09%
Veiligheid
Debt / Equity
0,97
Current Ratio0,64
Interest Coverage8,16
Waardering
P/E Ratio
29,18
P/B Ratio4,94
EV/EBITDA15,27
Dividend Yield0,02%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 14,98% | Revenue Growth (3Y) | 13,44% |
| Earnings Growth (1Y) | 21,90% | Earnings Growth (3Y) | 21,14% |
| Revenue Growth (5Y) | 12,19% | Earnings Growth (5Y) | 6,92% |
| Profitability | |||
| Revenue (TTM) | 2,26B | Net Income (TTM) | 152,11M |
| ROE | 17,99% | ROA | 6,42% |
| Gross Margin | 80,02% | Operating Margin | 15,09% |
| Net Margin | 6,72% | Free Cash Flow (TTM) | 327,41M |
| ROIC | 14,45% | FCF Growth (3Y) | 33,87% |
| Safety | |||
| Debt / Equity | 0,97 | Current Ratio | 0,64 |
| Interest Coverage | 8,16 | Dividend Yield | 0,02% |
| Valuation | |||
| P/E Ratio | 29,18 | P/B Ratio | 4,94 |
| P/S Ratio | 1,96 | PEG Ratio | 1,06 |
| EV/EBITDA | 15,27 | Dividend Yield | 0,02% |
| Market Cap | 4,44B | Enterprise Value | 5,22B |
Income Statement
Annual, most recent first
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | 2,26B | 1,97B | 1,76B | 1,68B | 1,43B |
| Net Income | 152,11M | 124,79M | 103,66M | 136,86M | 116,41M |
| EPS (Diluted) | 1,81 | 1,49 | 1,23 | 1,63 | 1,39 |
| Gross Profit | 1,81B | 1,57B | 1,38B | 1,34B | 1,15B |
| Operating Income | 341,68M | 648,84M | 575,63M | 583,61M | 179,23M |
Balance Sheet
Annual, most recent first
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Total Assets | 2,37B | 2,02B | 1,77B | 1,74B | 1,67B |
| Total Liabilities | 1,46B | 1,06B | 913,48M | 863,09M | 832,86M |
| Shareholders' Equity | 899,13M | 792,03M | 804,22M | 819,83M | 779,20M |
| Total Debt | 873,85M | 592,15M | 505,66M | 458,26M | 425,72M |
| Cash & Equivalents | 94,29M | 58,93M | 51,25M | 174,89M | 103,72M |
| Current Assets | 545,62M | 510,40M | 489,95M | 538,32M | 518,18M |
| Current Liabilities | 846,71M | 529,51M | 391,79M | 366,29M | 356,30M |
Strategiescores
This stock passed the criteria for 2 strategies
Score = fit strength (0–100)
Rank = position among all matches
Custom
Cash Flow Compounder
#439 of 1052
Custom
Balanced Risk
#142 of 151
Recente Activiteit
Ingestapt
Cash Flow Compounder
Mar 24, 2026
Ingestapt
Balanced Risk
Mar 24, 2026